Quinolones are a class of broad-spectrum antibiotics used to treat bacterial infections ranging from urinary tract infections to pneumonia. First discovered in 1962 with nalidixic acid and introduced for clinical use in 1967, they have since evolved through four generations, with the newer fluoroquinolones becoming some of the most widely prescribed antibiotics in the world.
How Quinolones Kill Bacteria
Bacteria need to copy their DNA to reproduce, and that process requires enzymes that unwind and manage the tightly coiled DNA strands. Quinolones target two of these essential enzymes: DNA gyrase and topoisomerase IV. Both enzymes work by temporarily cutting both strands of DNA, passing another strand through the gap, and then resealing the break.
Quinolones interfere with the resealing step. They wedge themselves into the complex where the enzyme meets the cut DNA, locking the break open. This does two things at once. First, the stuck enzyme physically blocks the machinery that copies DNA, halting replication. Second, the unrepaired double-strand breaks in the DNA become lethal to the bacterium. Rather than simply slowing bacteria down, quinolones actively destroy their DNA, which is why they are classified as bactericidal (bacteria-killing) rather than merely bacteriostatic (bacteria-slowing).
Interestingly, the primary target differs depending on the type of bacteria. In gram-negative bacteria (like E. coli), quinolones primarily hit DNA gyrase. In gram-positive bacteria (like staph and strep species), topoisomerase IV is the main target.
Four Generations of Quinolones
Each successive generation expanded the range of bacteria these drugs can fight.
- First generation includes nalidixic acid, the original quinolone. It is a narrow-spectrum drug effective only against certain gram-negative gut bacteria and was used mainly for uncomplicated urinary tract infections.
- Second generation is where fluoroquinolones begin. Adding a fluorine atom to the chemical structure dramatically improved potency and range. Ciprofloxacin and ofloxacin are the best-known examples. These drugs cover all gram-negative bacteria (including Pseudomonas in ciprofloxacin’s case), some gram-positive bacteria like Staphylococcus aureus, and atypical pathogens such as Mycoplasma and Chlamydia.
- Third generation drugs like levofloxacin keep the gram-negative coverage and add stronger activity against gram-positive bacteria, including strains of Streptococcus pneumoniae that resist penicillin.
- Fourth generation drugs like moxifloxacin cover everything the third generation does while adding activity against anaerobic bacteria, which thrive in low-oxygen environments like the abdomen.
Common Uses
Fluoroquinolones have been primary agents for treating urinary tract infections, digestive tract infections, and respiratory infections. They remain a mainstay for typhoid fever caused by Salmonella, largely because the bacteria have developed resistance to older antibiotics like ampicillin and chloramphenicol. Ciprofloxacin is commonly prescribed for complicated UTIs and certain gastrointestinal infections, while levofloxacin and moxifloxacin are frequently used for community-acquired pneumonia and sinus infections.
That said, because of their serious side effect profile, fluoroquinolones are generally reserved for infections where safer antibiotics are not an option. They are not recommended as first-line treatment for simple sinus infections, bronchitis, or uncomplicated UTIs when other choices exist.
Serious Side Effects and FDA Warnings
Fluoroquinolones carry an FDA boxed warning, the strongest safety warning a drug can receive. The warning covers multiple categories of harm that can be disabling and potentially irreversible, and these adverse effects can occur together.
Musculoskeletal and nerve problems include tendinitis and tendon rupture (the Achilles tendon is most commonly affected), muscle pain and weakness, joint pain and swelling, and peripheral neuropathy, which shows up as numbness, tingling, or a “pins and needles” sensation in the arms or legs.
Central nervous system effects can be equally serious: anxiety, insomnia, depression, confusion, hallucinations, psychosis, and suicidal thoughts have all been reported. These symptoms can appear within days of starting the medication and, in some cases, persist after the drug is stopped.
Fluoroquinolones also have a strong affinity for growing cartilage. Studies in the 1970s found that high doses caused joint damage in juvenile animals, which is why these drugs are generally avoided in children and during pregnancy. Human studies have not confirmed a clear increase in birth defects or joint problems in children exposed during pregnancy, but the animal data has been enough to keep the contraindication in place for most situations.
Interactions With Common Supplements
If you take a quinolone with certain minerals, your body may absorb dramatically less of the drug. Aluminum is the worst offender. Taking ciprofloxacin shortly after an aluminum-containing antacid reduced the amount of drug reaching the bloodstream by roughly 85%. When aluminum and magnesium were combined (as in some antacid formulations), absorption dropped by as much as 98%, essentially nullifying the antibiotic.
Calcium has a milder but still meaningful effect. Calcium carbonate supplements reduced ciprofloxacin absorption by about 40%. The interaction happens because these minerals bind to the quinolone molecule in the gut, forming a complex your body cannot absorb. To avoid this, quinolones should be taken at least two hours before or six hours after any product containing aluminum, magnesium, calcium, or iron. This includes antacids, multivitamins, and mineral supplements.
How Bacteria Become Resistant
Resistance to quinolones has been growing and works through several different pathways. The most common involves mutations in the genes that encode the drug’s targets. When the shape of DNA gyrase or topoisomerase IV changes even slightly, the quinolone can no longer bind effectively. Mutations in both targets at once can increase ciprofloxacin resistance more than tenfold.
Bacteria have also developed resistance through efflux pumps, molecular machines embedded in their cell walls that actively pump the antibiotic out before it can do damage. Some bacteria reduce the number of pores in their outer membrane, making it harder for the drug to enter in the first place. Perhaps most concerning, resistance genes can now travel between bacteria on plasmids, small loops of DNA that bacteria share with each other. This means resistance can spread not just from parent to offspring but horizontally between unrelated bacteria, accelerating the problem across species.
The spread of quinolone resistance is a significant public health concern, particularly in E. coli and other common gut bacteria, and is one more reason these antibiotics are increasingly reserved for situations where alternatives have failed or are unavailable.